Clofazimine exposure in vitro selects efflux pump mutants and bedaquiline resistance.

Clofazimine exposure in vitro selects efflux pump mutants and bedaquiline resistance.
Antimicrob Agents Chemother. 2019 Jan 14;:
Authors: Ismail N, Peters RPH, Ismail NA, Omar SV
Abstract
Six in-vitro clofazimine-resistant spontaneous mutants obtained from a wild-type or pyrazinamide-resistant ATCC reference strain were selected to evaluate bedaquiline cross-resistance. The reverse was conducted for bedaquiline mutants. All clofazimine mutants harbouring an rv0678 mutation displayed phenotypic cross-resistance. We observed the same for rv0678 bedaquiline mutants, however atpE bedaquiline mutants showed no phenotypic cross-resistance. This confirms that upfront clofazimine usage may impact subsequent bedaquiline use due to a shared efflux resistance pathway.
PMID: 30642938 [PubMed - as supplied by publisher]

Source: Antimicrobial Agents and Chemotherapy - January 14, 2019 Category: Microbiology Authors: Ismail N, Peters RPH, Ismail NA, Omar SV Tags: Antimicrob Agents Chemother Source Type: research